Search
Methylthioinosine
go.drugbank.com/drugs/DB02896ExperimentalAn analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
HSV-2 theracine
go.drugbank.com/drugs/DB05811ExperimentalHSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Deutarserine
go.drugbank.com/drugs/DB19057InvestigationalDeutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).
Crisugabalin
go.drugbank.com/drugs/DB19300InvestigationalCrisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to
APT3111
go.drugbank.com/drugs/DB06390ExperimentalAPT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).
Geneticin
go.drugbank.com/drugs/DB04263ExperimentalGeneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea. … Geneticin blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells and is commonly used in laboratory research to select genetically engineered cells.
LY-2599506
go.drugbank.com/drugs/DB05970InvestigationalLY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.
Synonyms: (R)-2-(4-(CYCLOPROPYLSULFONYL)PHENYL)-N-(PYRAZIN-2-YL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)PROPANAMIDETPI-ASM8
go.drugbank.com/drugs/DB05572InvestigationalTPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].